Kennan Marsh
AbbVie (United States)(US)
Publications by Year
Research Areas
Nicotinic Acetylcholine Receptors Study, Protein Kinase Regulation and GTPase Signaling, Receptor Mechanisms and Signaling, Synthesis and biological activity, Angiogenesis and VEGF in Cancer
Most-Cited Works
- → Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome(2006)906 cited
- → Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues: Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation(2002)420 cited
- → New inhibitors of renin that contain novel phosphostatine Leu-Val replacements(1990)102 cited
- → Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression(2007)81 cited
- → Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes(2005)77 cited
- → Synthesis and Structure−Activity Relationships of 2-Pyridones: A Novel Series of Potent DNA Gyrase Inhibitors as Antibacterial Agents(1996)75 cited
- → Structure−Activity Studies on 2-Methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): An Orally Bioavailable 3-Pyridyl Ether Nicotinic Acetylcholine Receptor Ligand with Cognition-Enhancing Properties(1997)67 cited
- → The synthesis and biological evaluation of a novel series of antimicrobials of the oxazolidinone class(2002)60 cited
- → ABT-963 [2-(3,4-Difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2 H-pyridazin-3-one], A Highly Potent and Selective Disubstituted Pyridazinone Cyclooxgenase-2 Inhibitor(2004)45 cited
- → Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer’s Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides(2017)34 cited